Eugene

[email protected]

LATEST

Novartis’ Sandoz Decides Not to Pursue Biosimilar of Roche’s Rituxan in the US
By

By
Sandoz, the generics arm of Novartis, has decided to not pursue its submission for a biosimilar to Roche’s Rituxan (rituximab) in the US at this time. The decision follows a…

Lonza Acquires Regenerative Medicine Company; Lubrizol, Thermo Fisher Expand
By

By
A roundup of the latest expansions and acquisition updates from suppliers, contract development and manufacturing organizations and contract manufacturing organizations, featuring news from Lubrizol, Lonza, and Thermo Fisher Scientific.  …

Novo Nordisk Plans Additional Job Cuts
By

By
Following previously announced plans to restructure its R&D organization, Novo Nordisk has announced that a number of additional restructuring initiatives across functions and geographies have been initiated to support the…

Astellas Begins Construction of New Facilities for Antibodies, Cell Therapies
By

By
Astellas Pharma has announced the construction of new research, development, and manufacturing facilities for biologic-based modalities, including antibodies and cell therapies, in Japan and Massachusetts. The facilities will produce clinical…

AstraZeneca, Innate Pharma Expand Oncology Pact; AstraZeneca Takes Equity Stake
By

By
AstraZeneca, and its global biologics research and development arm MedImmune, have formed a new multi-term agreement with Innate Pharma, a Marseille, France-based biopharmaceutical company, to build on an existing collaboration…

AstraZeneca To Divest Rights to GI Drugs Nexium in EU, Vimovo Worldwide
By

By
AstraZeneca has agreed to divest its rights in Europe to its gastroesophageal reflux disease drug, Nexium (esomeprazole), and its global rights (excluding the US and Japan) for its anti-inflammatory drug,…

Gilead Sciences, Tango Therapeutics in Immuno-Oncology Pact Worth up to $1.7 Billion
By

By
Gilead Sciences and Tango Therapeutics, a Cambridge, Massachusetts-based company developing cancer therapies, have partnered to discover, develop, and commercialize a pipeline of targeted immuno-oncology treatments, in a deal worth up…

Lilly, Dicerna Form RNAi Pact; Lilly Takes Equity Stake in Dicerna
By

By
Eli Lilly and Company and Dicerna Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company, have signed a multi-million-dollar pact to develop potential new medicines in the areas of cardio-metabolic disease, neurodegeneration, and…

FDA Issues CRL to Regeneron Over Manufacturing Issues of Eye-Disease Drug
By

By
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Regeneron Pharmaceuticals, a Tarrytown, New York pharmaceutical company, regarding manufacturing issues relating to a prefilled…

J&J Opens New Vaccine Launch Facility in the Netherlands
By

By
Johnson & Johnson (J&J) has opened a new vaccines launch facility in Leiden, the Netherlands. The facility uses technological and manufacturing platforms that can support large-scale production of vaccines for…